SCHEMBL4408300

SCHEMBL4408300

CC(O)CC[C@@H](N)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PMP22 Q01453 2/20 0.56
ALOX15 P16050 1/20 0.56
BLM P54132 1/20 0.56
KMT2A Q03164 1/20 0.56
BHMT Q93088 2/20 0.53
BHMT2 Q9H2M3 1/20 0.53
SLC1A3 P43003 3/20 0.52
SLC1A2 P43004 3/20 0.52
SLC1A1 P43005 3/20 0.52
GSR P00390 2/20 0.52
SLC7A5 Q01650 1/20 0.52
GRM8 O00222 1/20 0.52
GRM6 O15303 1/20 0.52
GRIN2D O15399 1/20 0.52
GRIN3B O60391 1/20 0.52
CYP1A2 P05177 1/20 0.52
GRIK1 P39086 1/20 0.52
GRM5 P41594 1/20 0.52
GRIA1 P42261 1/20 0.52
GRIA2 P42262 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL198716 1.00 PMP22 (0.56) PMP22ALOX15BLMKMT2ABHMT
SCHEMBL1512920 1.00 PMP22 (0.56) PMP22ALOX15BLMKMT2ABHMT
SCHEMBL198373 0.86 GSR (0.52) PMP22ALOX15BLMKMT2ABHMT
SCHEMBL25660446 0.86 GSR (0.56) PMP22ALOX15BLMKMT2ASLC1A3
SCHEMBL27458499 0.84 GSR (0.59) PMP22ALOX15BLMKMT2AGSR
SCHEMBL8068164 0.84 GSR (0.68) PMP22ALOX15BLMKMT2ABHMT
SCHEMBL602426 0.84 GSR (0.68) PMP22ALOX15BLMKMT2ABHMT
SCHEMBL59989 0.82 BHMT (0.55) PMP22ALOX15BLMKMT2ABHMT
SCHEMBL1895927 0.82 BHMT (0.55) PMP22ALOX15BLMKMT2ABHMT
SCHEMBL17039475 0.82 BHMT (0.55) PMP22ALOX15BLMKMT2ABHMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2036918-A1 PEPTIDE DERIVATIVE Vexon, Inc. (JP) 2009-03-18 EP claimed
US-20080009448-A1 Peptide Derivative VEXON, INC. (50%) (JP) 2008-01-10 US claimed
EP-2036918-A1 PEPTIDE DERIVATIVE Vexon, Inc. (JP) 2009-03-18 EP disclosed
US-20080009448-A1 Peptide Derivative VEXON, INC. (50%) (JP) 2008-01-10 US disclosed
WO-1999033864-A1 PEPTIDE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1999-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009448-A1 Peptide Derivative ARGLU1, NGLY1, NPR3 PMP22 3119/4885ALOX15 974/4885BLM 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.